Official Patient Website | TALVEY® (talquetamab-tgvs)
WEBView the official patient website and learn about TALVEY® (talquetamab-tgvs) for treatment in adult patients. See Full Prescribing, Safety Info & Boxed Warning.
U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class ...
WEBHORSHAM, Pa., Aug. 10, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of TALVEY™ (talquetamab-tgvs), a first-in-class bispecific antibody for the treatment of adult patients with relapsed or refractory multiple myeloma who ...
Official HCP Website | TALVEY® (talquetamab-tgvs) HCP
WEBTALVEY ® (talquetamab-tgvs) is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Talvey - European Medicines Agency (EMA)
WEBSep 21, 2023 · Talvey is a cancer medicine used to treat adults with multiple myeloma (a cancer of the bone marrow) when the cancer has come back (relapsed) and has not responded to treatment (refractory). It is used in patients who have received at least three previous therapies, including an immunomodulatory agent, a …
WEBTALVEY™ is a prescription medicine used to treat adults with multiple myeloma who: • have already received at least 4 treatment regimens, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody
talquetamab-tgvs for relapsed or refractory multiple myeloma
WEBOn August 9, 2023, the Food and Drug Administration granted accelerated approval to talquetamab-tgvs (Talvey, Janssen Biotech, Inc.) for adults with relapsed or refractory multiple myeloma who...
WEBTALVEY is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an...
TALVEY® (talquetamab-tgvs) - Janssen Science
WEBThis site provides access to current scientific information about TALVEY® (talquetamab-tgvs)
FDA approves TALVEY™ (talquetamab-tgvs) - The Antibody Society
WEBAug 10, 2023 · Talquetamab (JNJ-64407564) is a humanized, hinge-stabilized IgG4k/l T-cell engaging bispecific antibody with reduced effector function developed by Janssen. The antibody targets G protein-coupled receptor class C group 5 member D (GPRC5D), which is highly expressed in malignant plasma cells, and CD3 on T cells.
Talvey: Uses, How to Take, Side Effects, Warnings - Drugs.com
WEBNov 6, 2023 · Talvey is a bispecific GPRC5D-directed CD3 T-cell engager, which means that it targets GPRC5D on myeloma cells and CD3 on the surface of T cells. Talvey is used when cancer has not responded to treatment (refractory) or …